Adverum Biotechnologies (LTS:0HA3) EBIT per Share : $-10.91 (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Adverum Biotechnologies EBIT per Share?

Adverum Biotechnologies's EBIT per Share for the three months ended in Mar. 2024 was $-1.63. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-10.91.

During the past 3 years, the average EBIT per Share Growth Rate was 3.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was -4.10% per year. During the past 10 years, the average EBIT per Share Growth Rate was -7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Adverum Biotechnologies's EBIT per Share or its related term are showing as below:

LTS:0HA3' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -172.9 Med: -0.9 Max: 13.7
Current: 3.9

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Adverum Biotechnologies was 13.70% per year. The lowest was -172.90% per year. And the median was -0.90% per year.

LTS:0HA3's 3-Year EBIT Growth Rate is ranked better than
50.58% of 1303 companies
in the Biotechnology industry
Industry Median: 3.6 vs LTS:0HA3: 3.90

Adverum Biotechnologies's EBIT for the three months ended in Mar. 2024 was $-26.84 Mil.

Adverum Biotechnologies EBIT per Share Historical Data

The historical data trend for Adverum Biotechnologies's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies EBIT per Share Chart

Adverum Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-10.69

-13.85

-14.90

-15.83

-12.30

Adverum Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-3.02	-3.28	-3.42	-2.58	-1.63

Adverum Biotechnologies EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Adverum Biotechnologies's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-123.991	/	10.082
=	-12.30

Adverum Biotechnologies's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-26.839	/	16.479
=	-1.63

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.91

Adverum Biotechnologies (LTS:0HA3) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Adverum Biotechnologies EBIT per Share Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Adverum Biotechnologies (LTS:0HA3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (LTS:0HA3) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ADVM:USA

Address

100 Cardinal Way, Redwood CIty, CA, USA, 94063

Website

https://www.adverum.com

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies (LTS:0HA3) Headlines

No Headlines